Notable Labs

Notable Labs Equity

The The Equity of Notable Labs (NTBLQ) as of Nov 11, 2026 is 15.11 M USD. In the previous year, The Equity was 22.45 M USD — a change of -32.68% (lower).

Equity

15.11 MUSD

YoY

-32.68%

Last updated:

In 2023, Notable Labs's equity was 15.11 M USD, a -32.68% increase from the 22.45 M USD equity in the previous year.

The Notable Labs Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2016
42.40 M USD
Jan 1, 2017
55.90 M USD
Jan 1, 2018
53.09 M USD
Jan 1, 2019
36.02 M USD
Jan 1, 2020
30.92 M USD
Jan 1, 2021
52.18 M USD
Jan 1, 2022
22.45 M USD
Jan 1, 2023
15.11 M USD
The Notable Labs Equity history
YEAREquityYoY
15.11 MUSD-32.68%
22.45 MUSD-56.98%
52.18 MUSD+68.76%
30.92 MUSD-14.16%
36.02 MUSD-32.15%
53.09 MUSD-5.03%
55.90 MUSD+31.84%
42.40 MUSD+21.11%
35.01 MUSD-0.26%
35.10 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Notable Labs's Equity

Notable Labs's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Notable Labs's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Notable Labs's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Notable Labs's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Notable Labs’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Notable Labs stock

The Equity of Notable Labs is 15.11 M USD in 2023.

The Equity of Notable Labs changed from 22.45 M USD to 15.11 M USD, representing a -32.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Notable Labs since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Notable Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Notable Labs

All Key Metrics — Notable Labs